Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.

Automated microscopy and image analysis
Real-time, label free cell analysis
Nano and micro particle analysis

Accelerate to discover
Related topics
Extracellular Vesicle Purity Enhanced by Gen 2 qEV Columns With Customised Proprietary Resin
May 4, 2022
Izon Science has announced the launch of Gen 2, the enhanced range of qEV columns for size-exclusion...
May 3, 2022
A prodigy incorporating a unique combination of patent-pending innovative technologies that takes flow cytometry to the...
In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers
Mar 9, 2022
Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...
Introducing IsoPlexis Single-Cell Natural Killer Panel
Mar 4, 2022
Because of their ability to kill tumour cells, NK cells are an attractive target in cancer immunotherapy, therapeutic...
Enhanced small particle detection on CytekAurora and Northern Lights
Mar 2, 2022
Aurora system with ESP option, can fully resolve particles around 70nm and from the 80nm PS bead. The new violet laser...
Multi-modal PET drives interdisciplinary preclinical imaging
Feb 23, 2022
Preclinical imaging (PCI) plays a vital role in understanding the biological processes behind disease states at the...
Quantitative 3D Optical Imaging for Lago
Feb 21, 2022
Spectral Instrument Imaging just announced a new, strategic partnership with InVivo Analytics, which enables...
Reduces fMRI-BOLD Response in the Brain
Feb 18, 2022
fMRI studies often involve the electrical stimulation of i.e. the forepaw, detecting where this stimulation is...
May 18, 2020
The Pim family of serine/threonine protein kinases (Pim 1, 2, and 3) contribute to cellular transformation by regulating glucose metabolism, protein synthesis, and mitochondrial oxidative phosphorylation. Drugs targeting the Pim protein kinases are being tested in phase I/II clinical trials for the treatment of hematopoietic malignancies. The goal of these studies was to identify Pim substrate(s) that could help define the pathway regulated by these enzymes and potentially serve as a biomarker of Pim activity. To identify novel substrates, bioinformatics analysis was carried out to identify proteins containing a consensus Pim phosphorylation site. This analysis identified the insulin receptor substrate 1 and 2 (IRS1/2) as potential Pim substrates.
Experiments were carried out in tissue culture, animals, and human samples from phase I trials to validate this observation and define the biologic readout of this phosphorylation. Our study demonstrates in both malignant and normal cells using either genetic or pharmacological inhibition of the Pim kinases or overexpression of this family of enzymes that human IRS1S1101 and IRS2S1149 are Pim substrates. In xenograft tumor experiments and in a human phase I clinical trial, a pan-Pim inhibitor administered in vivo to animals or humans decreased IRS1S1101 phosphorylation in tumor tissues. This phosphorylation was shown to have effects on the half-life of the IRS family of proteins, suggesting a role in insulin or IGF signaling. These results demonstrate that IRS1S1101 is a novel substrate for the Pim kinases and provide a novel marker for evaluation of Pim inhibitor therapy.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Get more info
Brand profile
Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.
More info at:
https://spectralinvivo.com/